419 related articles for article (PubMed ID: 33761782)
1. Human NK cells: From development to effector functions.
Perera Molligoda Arachchige AS
Innate Immun; 2021 Apr; 27(3):212-229. PubMed ID: 33761782
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells: Development, Maturation, and Clinical Utilization.
Abel AM; Yang C; Thakar MS; Malarkannan S
Front Immunol; 2018; 9():1869. PubMed ID: 30150991
[TBL] [Abstract][Full Text] [Related]
3. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
4. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections.
Terunuma H; Deng X; Dewan Z; Fujimoto S; Yamamoto N
Int Rev Immunol; 2008; 27(3):93-110. PubMed ID: 18437601
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell responses to viral infection.
Brandstadter JD; Yang Y
J Innate Immun; 2011; 3(3):274-9. PubMed ID: 21411975
[TBL] [Abstract][Full Text] [Related]
6. Tuning the threshold of natural killer cell responses.
Narni-Mancinelli E; Ugolini S; Vivier E
Curr Opin Immunol; 2013 Feb; 25(1):53-8. PubMed ID: 23270590
[TBL] [Abstract][Full Text] [Related]
7. Memory-like natural killer cells for cancer immunotherapy.
Gang M; Wong P; Berrien-Elliott MM; Fehniger TA
Semin Hematol; 2020 Oct; 57(4):185-193. PubMed ID: 33256911
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
9. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
10. Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.
Zhao X; Cai L; Hu Y; Wang H
Front Immunol; 2020; 11():584099. PubMed ID: 33193399
[TBL] [Abstract][Full Text] [Related]
11. From the "missing self" hypothesis to adaptive NK cells: Insights of NK cell-mediated effector functions in immune surveillance.
Cruz-Muñoz ME; Valenzuela-Vázquez L; Sánchez-Herrera J; Santa-Olalla Tapia J
J Leukoc Biol; 2019 May; 105(5):955-971. PubMed ID: 30848847
[TBL] [Abstract][Full Text] [Related]
12. NK cells in host responses to viral infections.
Lam VC; Lanier LL
Curr Opin Immunol; 2017 Feb; 44():43-51. PubMed ID: 27984782
[TBL] [Abstract][Full Text] [Related]
13. Human natural killer cells: Form, function, and development.
Mace EM
J Allergy Clin Immunol; 2023 Feb; 151(2):371-385. PubMed ID: 36195172
[TBL] [Abstract][Full Text] [Related]
14. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
Michen S; Temme A
Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.
Zhang J; Zheng H; Diao Y
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646574
[TBL] [Abstract][Full Text] [Related]
16. Innate or adaptive immunity? The example of natural killer cells.
Vivier E; Raulet DH; Moretta A; Caligiuri MA; Zitvogel L; Lanier LL; Yokoyama WM; Ugolini S
Science; 2011 Jan; 331(6013):44-9. PubMed ID: 21212348
[TBL] [Abstract][Full Text] [Related]
17. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
18. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
19. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
